Prophylactic HIV Drugs Market on Track for Substantial Growth, Predicted to Exceed USD 48,822.4 Million by 2033 at a 4.1% of CAGR

The prophylactic HIV drugs market is witnessing significant expansion, with robust growth projected in the coming decade. In 2023, the market size reached an estimated USD 32,516.1 million, driven by increased investment in HIV research and development, rising drug approvals, and a surge in HIV incidence rates.

According to Future Market Insights, the market is forecasted to expand at a Compound Annual Growth Rate (CAGR) of 4.1% between 2023 and 2033, reaching a valuation of approximately USD 48,822.4 million by 2033. This growth trajectory underscores the critical importance of prophylactic HIV drugs in combating the global HIV/AIDS epidemic.

Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9582

Global sales of HIV prophylaxis drugs are projected to reach a value of about USD30 billion by 2021. Owing to growing awareness of HIV and the rising prevalence of HIV infection worldwide, As for AIDS prevention, between 2022 and 2032, the market for preventative HIV drugs grew at a compound annual growth rate (CAGR) of 4%, reaching USD 40 billion in 2028.

HIV has been a major global cause of death for many years, impacting millions of people. People whose immune systems are compromised by the virus are more susceptible to a range of ailments and cancers. HIV can be controlled even when there isn’t a long-term cure by expanding access to adequate care, diagnosis, medication, and prevention.

Prophylactic HIV Drugs: A Powerful Prevention Tool

Effective management techniques are available for HIV, even though a long-term cure is still unattainable. One of the most important aspects of fighting the virus is expanding access to care, diagnosis, treatment, and prevention services. HIV prevention medications are becoming an essential weapon in the fight against HIV infection. These cutting-edge treatments work especially well at preventing HIV transmission through drug injection and sexual contact.

Focus on Pre-Exposure Prophylaxis (PrEP):

Pre-Exposure Prophylaxis (PrEP), one of the preventive HIV medications, is becoming increasingly popular because of its great effectiveness. The risk of HIV infection from sex and injectable drug use can be considerably decreased with PrEP, according to the Centers for Disease Control and Prevention (CDC), by 74% and 99%, respectively. The extraordinary efficacy of PrEP is spearheading a global movement for its expanded usage.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-9582

Market Competition:

Some of the prominent players operating in the global market are-

• Gilead Sciences, Inc
• Merck Sharp & Dohme Corp.
• Merck & Co. Inc.
• Mylan NV
• Cipla Inc.
• Genentech Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Health Care Systems Inc
• Pfizer Inc.
• GalaxoSmithKline PLC

Notable Developments of the Key Players in the Market

• In April 2023, Merck & Co (MRK.N) confirmed that it is going to buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, by picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up its presence in immunology.
• In November 2022, Merck, known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, might acquire Imago for US$ 36.00 per share in cash for around total equity value of US$ 1.35 billion.

Key Companies Profiled:

• Gilead Sciences, Inc
• Merck Sharp & Dohme Corp.
• Merck & Co. Inc.
• Mylan NV
• Cipla Inc.
• Genentech Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Health Care Systems Inc
• Pfizer Inc.
• GalaxoSmithKline PLC

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey:

By Drug Class:

• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
• Integrase Inhibitor

By Distributional Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies
• Drug Stores

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan
• Japan
• The Middle East and Africa